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Abstract  30 
Increasing levels of estrogen and progesterone are suggested to play a role in the gender switch in 31 
asthma prevalence during puberty. We investigated whether the process of sexual maturation in 32 
mice affects the development of lung inflammation in adulthood and the contributing roles of 33 
estrogen and progesterone during this process.  34 
By inducing ovalbumin-induced lung inflammation in sexually mature and immature (ovariectomized 35 
before sexual maturation) adult mice, we showed that sexually immature adult mice developed more 36 
eosinophilic lung inflammation. This protective effect of ‘puberty’ appears to be dependent on 37 
estrogen, as estrogen substitution at the time of ovariectomy protected against development of lung 38 
inflammation in adulthood while progesterone substitution did not. Investigating the underlying 39 
mechanism of estrogen-mediated protection, we found that estrogen-treated mice had higher 40 
expression of the anti-inflammatory mediator secretory leukoprotease inhibitor (SLPI) and lower 41 
expression of the pro-asthmatic cytokine IL-33 in parenchymal lung tissue and that their expressions 42 
colocalized with type II alveolar epithelial. Cells (AECII) Treating AECII directly with SLPI significantly 43 
inhibited IL-33 production upon stimulation with ATP.  44 
Our data suggest that estrogen during puberty has a protective effect on asthma development, 45 
which was accompanied by induction of anti-inflammatory SLPI production and inhibition of pro-46 
inflammatory IL-33 production by AECII. 47 
48 
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Introduction 49 
Asthma prevalence is higher in boys than in girls during early childhood (1, 2, 3, 4). At the onset of 50 
puberty, however, this sex difference reverses (11, 13, 20, 48, 60). Adult asthma is not only more 51 
common in women, but asthma is also more severe in women than men (27, 48, 52, 62). Female sex 52 
hormones, i.e. estrogen and progesterone, have been linked to the higher risk of girls to develop 53 
asthma during puberty, when hormone levels increase (7). Girls with an earlier menarche have a 54 
higher risk of developing asthma, which may be explained by exposure to greater cumulative 55 
estrogen and progesterone levels than girls with late menarche (25, 28, 46, 58). These studies clearly 56 
suggest a role of estrogen and progesterone in asthma development and severity, yet experimental 57 
findings are anything but clear. 58 
Some studies report worsening of asthma in women when estrogen and progesterone levels are 59 
high, and others that low hormone levels coincide with worse asthma symptoms (6, 14, 16, 29, 30, 60 
39, 40, 43). Contradictory results were also found in animal studies using mice and rats. Both pro-61 
inflammatory and anti-inflammatory effects of estrogen and progesterone have been reported in 62 
mouse and rat models of asthma with a variety of explanations for these conflicting results (8, 18, 26, 63 
35, 37, 38, 44). However, little is known about how puberty per se affects asthma development later 64 
in life and how the changes in either estrogen or progesterone levels during puberty affect asthma 65 
development.  66 
This is of interest as estrogen can have direct effects on the immune system by binding to estrogen 67 
receptors expressed by several immune cells (10). Additionally, estrogen can influence airway 68 
responses indirectly by acting on structural cells, such as airway epithelial cells. In response to 69 
inhaled allergen, airway epithelial cells induce nuclear factor (NF)-B-signaling and subsequently 70 
recruit and activate immune cells through production of pro-asthmatic mediators such as IL-33 and 71 
TSLP (17, 23). To protect the airways against escalating inflammation and subsequent damage, 72 
epithelial cells also secrete anti-inflammatory factors such as secretory leukoprotease inhibitor (SLPI) 73 
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(31). SLPI exerts its anti-inflammatory effects via inhibition of NF-B-signaling. Interestingly, SLPI 74 
expression has been found to be upregulated by estrogen treatment (9, 54, 55), but has not been 75 
linked to IL-33 signaling yet.  76 
We investigated the development of allergic lung inflammation subsequent to ovalbumin challenge 77 
in adult female mice that did not go through puberty and assessed whether the increase in estrogen 78 
or progesterone levels during puberty affect the severity of allergic lung inflammation in female adult 79 
mice. Our studies showed that going through puberty actually leads to less severe lung inflammation 80 
in adult female mice as compared to mice going through puberty. In addition, we also found that 81 
allergic lung inflammation is inhibited by a sole increase in estrogen during puberty, but was not 82 
affected by a sole increase in progesterone during puberty. This inhibition is associated with higher 83 
SLPI expression that appears to inhibit the production of the pro-inflammatory cytokine IL-33. 84 
85 
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Materials and methods 86 
Animals 87 
Female BALB/c mice (aged 3 weeks) were obtained from Harlan (Horst, The Netherlands). The mice 88 
were fed ad libitum with standard food and water and were kept in a temperature and light-89 
controlled room (lights on from 7.30 am until 7.30 pm). Animal procedures were approved by the 90 
Institutional Animal Care and Use Committee of the University of Groningen (application number 91 
4609) and were performed under strict governmental and international guidelines. All surgeries were 92 
performed under isoflurane/oxygen anesthesia and all efforts were made to minimize suffering 93 
including the use of buprenorphine for pain management after surgery. 94 
  95 
Ovariectomy and OVA model 96 
Female BALB/c mice were ovariectomized (OVX) or sham-treated (SHAM) at 28 days of age before 97 
reaching sexual maturity (around day 35). OVX animals were either left untreated or subcutaneously 98 
received a 60-day slow release pellet of 0.1 mg estrogen (OVX+E2) or 15 mg progesterone (OVX+P) 99 
(IRA, Sarasota, FL, USA) at the time of ovariectomy. These E2 and P pellets were chosen because they 100 
have been shown to yield plasma levels about two times higher (E2 ±350 pg/ml, P ±55 ng/ml) than 101 
levels at estrus (for E2 ±150 pg/ml and for P ±25 ng/ml) (50). Uterine weight was assessed to check to 102 
quality of ovariectomy, estrogen and progesterone treatment (see figure S1 of the supplemental 103 
data). Ovariectomy strongly reduced uterine weight as compared to sham treatment. Estrogen 104 
treatment mostly prevented this low uterine weight, and progesterone treatment led to slightly, but 105 
significantly, higher uterine weight as compared to ovariectomy. Animals with normal (>40 mg) 106 
uterine weights after ovariectomy were excluded from the studies, as were animals with low (<15 107 
mg) uterine weights after estrogen (indicating the pellet did not work) and or high (>50 mg) uterine 108 
weights after progesterone treatment (indicating that ovariectomy was not performed successfully).  109 
Four weeks after ovariectomy (age 8 weeks), mice were sensitized intraperitoneally to 10 g of 110 
ovalbumin (OVA, Grade V, Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) and 1.5 mg of 111 
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alum (Aluminject, Pierce Chemical, Etten-Leur, The Netherlands) on days 1 and 7, followed on day 112 
14-20 by daily 20-min aerosol challenges with 1% w/v OVA in sterile PBS using a Pari LC Sprint Star 113 
nebulizer driven by a PARI Boy SX compressor (both kind gifts from Pari GmbH, Starnberg, Germany). 114 
Healthy controls (n=8) were not sensitized with alum and were exposed to PBS. An overview of the 115 
experimental design is depicted in figure 1.  116 
On day 21 (age 11 weeks), serum was collected for OVA-specific IgE and animals were either 117 
sacrificed to collect bronchoalveolar lavage fluid and to isolate lung cells from digested lung for flow 118 
cytometry or sacrificed for histological analyses of lung tissue. The experimental groups consisted of 119 
32 SHAM mice (15 for lavage/flow and 17 for histology), 18 OVX mice (10 for lavage/flow and 8 for 120 
histology), 11 OVX+E2 mice (6 for lavage/flow and 5 for histology), and 14 OVX+P (6 for lavage/flow 121 
and 8 for histology). 122 
 123 
OVA-specific IgE 124 
Serum levels of OVA-specific IgE were measured by ELISA as described previously (33). OVA-specific 125 
IgE titers are expressed as arbitrary ELISA units that were interpolated from a standard curve of a 126 
reference serum.  127 
 128 
Bronchoalveolar lavage fluid 129 
Bronchoalveolar lavage fluid was collected and cells were processed for cytospots to determine the 130 
percentage of eosinophils as described previously (33). Total and differential cell counts can be found 131 
in table S2 of the supplemental data. Lavage supernatants were used to assess the levels of secretory 132 
leucocyte protease inhibitor (SLPI) and IL-33.  133 
SLPI levels in lavage supernatants were determined by western blot analysis using a biotinylated goat 134 
polyclonal α-SLPI antibody (R&D Systems, Oxon, UK). Briefly, equal amounts of total protein (25 µg) 135 
were run on a 15% SDS-PAGE gel and subsequently transferred to polyvinylidene difluoride 136 
membranes (Roche, Mannheim, Germany). The membranes were blocked with 5% blotting grade 137 
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non-fat milk (Biorad, Veenendaal, Netherlands) and incubated with an anti-SLPI antibody overnight 138 
(in 5% milk). Next, the blots were incubated with rabbit-anti-goat HRP-conjugated secondary 139 
antibody followed by a goat-anti-rabbit HRP-conjugated tertiary antibody (both DAKO, Glostrup, 140 
Denmark). Blots were subsequently developed using sensitive Western Lightning-ECL reagent 141 
(Perkin-Elmer, Boston, MA) in a G-Box (Syngene, Cambridge, U.K.). Molecular weights were 142 
estimated based on the migration of ten known molecular weight standards (Biorad, Veenendaal, 143 
The Netherlands). Digital evaluation of blots was performed by GeneTools analysis software 144 
(Syngene, Cambridge, U.K.), which assigns a peak height to each band. The relative SLPI expression is 145 
described as SLPI expression in lavage fluid of OVX and OVX+E2 mice in relation to the SLPI 146 
expression in lavage fluid of SHAM mice.  147 
The levels of IL-33 in lavage supernatants were determined by ELISA kits according to the 148 
manufacturer’s instructions (R&D Systems).  149 
 150 
Lung digestion 151 
After bronchoalveolar lavage, lungs were minced and incubated in RPMI medium supplemented with 152 
10% fetal calf serum (both Lonza, Verviers, Belgium), 10 μg/ml DNAse I (grade II from bovine 153 
pancreas, Roche Applied Science, Almere, Netherlands), and 0.7 mg/ml collagenase A (Sigma-Aldrich) 154 
for 45 min at 37°C in a shaking water bath. Single cell suspensions of lungs were obtained by passing 155 
the digested lung tissue through a 70 μm nylon strainer (BD Biosciences, Breda, Netherlands). 156 
Contaminating erythrocytes were lyzed using 10 times diluted Pharmlyse (BD Biosciences). 157 
Mononuclear cells were then enriched by performing discontinuous Percoll (Pharmacia, Uppsala, 158 
Sweden) gradient centrifugation (20 to 55%). Cells collected on the 55% and 45% layers were passed 159 
through a 35 μm nylon strainer (BD Biosciences) and counted using a Sysmex pocH-100i cell counter 160 
(Sysmex, Roche, Germany). Total cell counts can be found in table S3 of the supplemental data. Cells 161 
were subsequently used for flow cytometry. 162 
 163 
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 165 
Flow cytometric analysis  166 
The single lung cell suspensions were stained for T-cell subsets and macrophages using two different 167 
mixes of antibodies for flow cytometry. 168 
Frequencies of effector T cells (CD3+CD4+CD25+Foxp3-) and regulatory T cells 169 
(CD3+CD4+CD25+Foxp3+) were examined using anti-CD3-Pacific Blue (Biolegend, Fell, Germany), 170 
anti-CD4-PerCP (BD), anti-CD25-APC (BD), and anti-Foxp3-FITC (eBioscience, Vienna, Austria). An 171 
appropriate isotype control was used for the Foxp3 staining (rat IgG2a-FITC, eBioscience). In addition, 172 
frequencies of B cells (CD3-CD19+) were examined using anti-CD19-PE/Cy7 in this mix. 173 
Frequencies of macrophages (autofluorescent+F4/80+CD11c+) and activated macrophages 174 
(autofluorescent+F4/80+CD11c+MHCII+) were examined by using autofluorescence in the FITC 175 
channel and using biotin-labeled anti-MHC class II (BD Biosciences) followed by PerCP-labeled 176 
streptavidin (BD Biosciences), PE-labeled anti-CD11c (Biolegend) and pacific blue-labeled anti-F4/80 177 
(Biolegend) (59). 178 
Before staining with surface markers, 106 cells per 25 μl were first incubated for 15 minutes on ice 179 
with cold 10% normal mouse serum in phosphate buffered saline solution (PBS) to block aspecific 180 
binding. Cells were subsequently incubated with the appropriate antibody mix for 30 minutes on ice, 181 
protected from light. After washing the cells with PBS supplemented with 2% FCS, the macrophage 182 
cell mix was incubated for 15 minutes with Streptavidin-PerCP, washed three times with PBS/2%FCS, 183 
resuspended in FACS lysing solution (BD Biosciences), and kept in the dark on ice until flow cytometry 184 
analysis. The cells of the T-cell mix were fixed and permeabilized for 30 minutes using a fixation and 185 
permeabilization buffer kit (eBioscience), and then washed with permeabilization buffer, blocked 186 
with 2% normal mouse serum and then incubated with anti-Foxp3 for 30 min. Thereafter the cells 187 
were washed with permeabilization buffer, resuspended in FACS lysing solution, and kept in the dark 188 
on ice until flow cytometric analysis. The fluorescent staining of the cells was measured on a LSR-II 189 
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flow cytometer (BD Biosciences) and data were analyzed using FlowJo Software (Tree Star, Ashland, 190 
USA). Examples or our gating strategy can be found in figure S4 and S5 of the supplemental data. 191 
 192 
Histology  193 
During sacrifice, the trachea was cannulated and both lungs were carefully inflated with 50% Tissue-194 
Tek O.C.T. compound (Sakura, Finetek Europe B.V., Zoeterwoude, The Netherlands) in PBS and 195 
the right lung was snap-frozen for histological analysis and the left lung fixed in formalin.  196 
The number of IL-33-producing cells was determined in 4 µm cryosections of lung tissue with a goat 197 
polyclonal anti-IL-33 antibody and SLPI-producing cells were identified with a biotinylated goat 198 
polyclonal anti-SLPI antibody (both R&D Systems). The number of the IL-33-producing cells and 199 
intensity of SLPI-staining was measured separately in the infiltrates and parenchyma of whole tissue 200 
sections using ImageScope software (Aperio, Vista, CA, USA). Type II alveolar epithelial (AEC type II) 201 
cells were identified with a polyclonal rabbit anti-Pro-surfactant protein C antibody (anti-pro-SPC, 202 
Millipore, Amsterdam, Netherlands) and were double-stained with either anti-IL-33 or anti-SLPI using 203 
standard immunohistochemical procedures.  204 
To determine the number of eosinophils in lavage fluid a Giemsa staining (Sigma-Aldrich) was 205 
performed on cytospots. The number of eosinophils was counted in a total of 300 cells and the 206 
percentage of eosinophils was used to calculate the absolute number of eosinophils as a fraction of 207 
total cells in lavage fluid.  208 
 209 
Epithelial cell line  210 
The murine type-II alveolar epithelial-like cell line C10 was a kind gift from Dr. H.I. Heijink 211 
(Department of Allergology, University Medical Center Groningen, The Netherlands). The cells were 212 
cultured in RPMI (Lonza) supplemented with 10% FCS and gentamycin under 5% CO2 at 37° according 213 
to standard protocols.  214 
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C10 cells were plated into 12-wells plates at a density of 5 x 105 cells/well. At 90% confluence, the 215 
cells were starved for 24 hours. The cells were pre-incubated or not with human SLPI (10 µg/ml, R&D 216 
Systems) for 1 hour and subsequently stimulated with ATP (100 µg/ml, Sigma) or were not treated 217 
(control). After 24 hours, the cells were harvested and sonicated and levels of IL-33 were determined 218 
by ELISA (R&D Systems).  219 
 220 
Statistical Analysis 221 
Data are represented as mean ± standard error of the mean. To determine the normality of the data 222 
the Kolmogorov-Smirnov test was used. Data were log-transformed to fit a normal distribution when 223 
not normally distributed. Differences between groups were tested using a one-way ANOVA followed 224 
by Sidak’s multiple comparisons test to compare Healthy vs SHAM, SHAM vs. OVX, OVX vs. OVX+E2, 225 
and OVX vs. OVX+P. P-values <0.05 were considered to be statistically significant. 226 
227 
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Results 228 
The process of sexual maturation dampens the severity of OVA-induced lung inflammation in adult 229 
female mice  230 
To test whether preventing puberty would affect development of allergic lung inflammation in adult 231 
mice we ovariectomized mice (OVX) or sham-treated them (SHAM) before they reached sexual 232 
maturity. After inducing lung inflammation in these animals in adulthood we quantified a number of 233 
parameters of allergic lung inflammation.  234 
General histology showed that sham-treated, ovariectomized and ovariectomized + progesterone-235 
treated mice responded to OVA challenges with lung inflammation as compared to healthy controls. 236 
Especially lungs of sham-treated and ovariectomized mice, and to a lesser extent ovariectomized + 237 
progesterone-treated, showed thickening of the alveolar walls. Ovariectomized + estrogen-treated 238 
mice demonstrated less lung inflammation and no thickening of the alveolar walls (figure 2).  239 
Our previous studies showed that the severity of allergic lung inflammation correlated strongly with 240 
increased presence of eosinophils, (activated) macrophages, effector T lymphocytes, regulatory T 241 
lymphocytes and B lymphocytes in lung tissue (32–34). We therefore quantified these inflammatory 242 
cells in lavage fluid and lung tissue to assess severity of inflammation. Higher numbers of eosinophils, 243 
(activated) macrophages, effector T lymphocytes, regulatory T lymphocytes and B lymphocytes were 244 
induced in lungs of OVA-exposed SHAM-treated mice as compared to healthy controls (figure 3). We 245 
found higher numbers of eosinophils in lavage fluid and (activated) macrophages and B lymphocytes 246 
in lung tissue of ovariectomized mice compared to sham-treated mice. Significantly lower numbers of 247 
these cells were found in lung tissue of ovariectomized + estrogen-treated mice as compared to 248 
untreated ovariectomized mice (figure 3A-D). Higher levels of OVA-specific IgE levels were found in 249 
OVA-exposed SHAM-treated mice as compared to healthy controls. OVA-specific IgE levels in serum 250 
were not significantly affected by ovariectomy, but treating ovariectomized mice with estrogen also 251 
led to significantly lower levels as compared to untreated ovariectomized mice. Ovariectomized + 252 
progesterone-treated mice and untreated ovariectomized mice had similar levels of OVA-specific IgE 253 
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(figure 3E). While ovariectomy did not affect numbers of effector and regulatory T lymphocytes, 254 
treatment with estrogen led to significantly lower numbers of these cells in lung tissue as compared 255 
to untreated ovariectomized mice. Progesterone treatment of ovariectomized mice did not affect 256 
any of the aforementioned cells (figure 3F and G). 257 
 258 
Estrogen treatment increases SLPI expression and decreases IL-33 production in alveolar epithelial 259 
cells in mice ovariectomized before puberty 260 
Based on our recent studies and in order to explain the mechanism behind this estrogen modulation 261 
of lung inflammation we focused on secretory leukoprotease inhibitor (SLPI), an anti-inflammatory 262 
factor that is known to be upregulated by estrogen in airway epithelial cells 9). We therefore studied 263 
the expression of both SLPI in lung tissue in combination with the expression of the pro-asthmatic 264 
cytokine IL-33. SLPI is an inhibitor of NFkB, which in turn regulates expression of IL-33.  Double 265 
stainings of lung tissue for these two mediators showed that both IL-33 and SLPI colocalize with pro-266 
SPC, a marker for type II alveolar epithelial cells (figure 4), indicating that IL-33 and SLPI have a similar 267 
source, namely the type II alveolar epithelial cells. 268 
The SLPI levels we determined in lavage fluid of control mice were too low to be detected but these 269 
levels increased significantly in mice subjected to OVA-induced lung inflammation (figure 5A and B). 270 
Ablating estrogen before sexual maturity led to lower SLPI levels in lavage fluid of ovariectomized 271 
mice as compared to sham-treated mice. Subsequently treating ovariectomized mice with estrogen 272 
restored higher SLPI levels as compared to untreated ovariectomized mice. We also tried to assess IL-273 
33 in lavage fluid, but found no detectable levels (data not shown). 274 
We then quantified the number of SLPI-and IL-33 producing cells in parenchymal lung tissue to assess 275 
if the number of cells producing these mediators had changed. The expression of SLPI in parenchymal 276 
lung tissue was similarly low in healthy mice, sham-treated mice and ovariectomized mice, but 277 
ovariectomized + estrogen-treated mice had significantly more cells expressing SLPI than untreated 278 
ovariectomized mice (figure 5C).  279 
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Higher numbers of IL-33-producing cells were found in lung tissue of OVA-exposed SHAM-treated 280 
mice as compared to healthy controls. The number of IL-33-producing cells was comparable in 281 
ovariectomized mice and sham-treated mice, but was lower in parenchymal tissue of ovariectomized 282 
+ estrogen-treated mice as compared to untreated ovariectomized mice (Figure 5D). A double 283 
staining of SLPI and IL-33 showed that there are almost no cells that expressed both SLPI and IL-33 at 284 
the same time. Figure 5E shows an example of the double staining on lungs of ovariectomized + 285 
estrogen-treated mice (figure 5E).  286 
 287 
SLPI decreases IL-33 production in alveolar epithelial type II cells 288 
To determine the direct effect of SLPI on IL-33 production, the murine C10 cell line (alveolar type II 289 
cells) was treated with ATP, a danger signal that is an important effector molecule in the OVA model 290 
of allergic lung inflammation, to induce the production of IL-33 (21). Untreated cells and cells treated 291 
with SLPI alone were used as controls. We were unable to find any secreted IL-33 (data not shown) 292 
and found all IL-33 present within cells. The amount of IL-33 in C10 type II epithelial cells was 293 
significantly higher after treatment with ATP. After SLPI treatment, the ATP-induced IL-33 production 294 
by C10 cells was significantly lower (Figure 6).  295 
296 
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Discussion 297 
Before puberty more boys suffer from asthma than girls, while this distribution changes during 298 
puberty and more females develop asthma after puberty and suffer from more severe disease as 299 
compared to males (1, 2, 13, 20, 27, 48, 60). Although many studies have focused on the female sex 300 
hormones estrogen and progesterone to explain this dichotomy, their roles remain inconclusive. We 301 
found that preventing sexual maturation by ablating sex hormones before “puberty” in mice 302 
significantly increased the number of eosinophils and B lymphocytes as compared to sham-treated 303 
mice, suggesting that the process of sexual maturation actually ameliorates some aspects of 304 
subsequent lung inflammation in adult mice. Interestingly, this beneficial effect of sexual maturation 305 
appears to solely depend on estrogen, as estrogen but not progesterone substitution after 306 
ovariectomy inhibited lung inflammation. This effect of estrogen is associated with higher production 307 
of SLPI and lower production of IL-33 by cells in lung parenchyma. Our further findings showed that 308 
SLPI could directly inhibit IL-33 production in alveolar epithelial cells explaining how estrogen may 309 
play a protective role in the development of lung inflammation.  310 
Similar as seen in humans, female mice develop more severe allergic lung inflammation than male 311 
mice and therefore this model was used to study effects of sexual maturation and sex hormones in 312 
asthma development (34). Contrary to our findings, previous studies on rat and mouse ovalbumin-313 
induced allergic airway inflammation have shown that depletion of sex hormones before 314 
sensitization inhibits lung inflammation and that treatment with estrogen before and during 315 
ovalbumin immunization re-established lung inflammation in these ovariectomized animals (26, 37, 316 
44). In addition, both pro-and anti-inflammatory effects of progesterone on asthma development 317 
have been described (18, 35, 37). These previous studies have in common that ovariectomy or 318 
hormone treatments were performed in adult animals with different timings of 319 
ovariectomy/treatment with respect to induction of lung inflammation, which may be an important 320 
determinant in the outcome of those studies. Since we focused on the relationship between 321 
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increasing estrogen and progesterone levels during puberty and the development of lung 322 
inflammation, we performed ovariectomy and started estrogen or progesterone treatment before 323 
sexual maturation and induced lung inflammation in adulthood. Contrary to our expectations, our 324 
data clearly showed that the hormone-driven process of sexual maturation ameliorates some aspects 325 
of the development of lung inflammation in adulthood. The disparity with the clinical situation may 326 
be explained by the observational nature of the clinical studies and the fact that sexual maturation in 327 
humans is a multi-factorial process that involves more than just an elevation of and the start of 328 
cycling of sex hormones.  329 
An explanation for the protective effect of hormone-driven sexual maturation may be found in the 330 
changes in expression of immune genes that was shown to occur during sexual maturation in mice 331 
(22). Lamason et al. showed a sexual dimorphism in innate and adaptive immune functions in post-332 
pubertal mice, which was dependent on puberty. Female mice had higher expression of adaptive 333 
immune genes while males had higher expression of innate immune genes after sexual maturation. 334 
The ovariectomy that we performed before this “puberty”-induced difference in immune function 335 
could occur, may have prevented the upregulation of genes of the adaptive immune system and 336 
thereby make female mice more susceptible to allergic lung inflammation. Here we did not study the 337 
expression of immune genes, but it would be interesting to know what happens after substitution of 338 
estrogen and progesterone, even though this would be without the natural cycling changes in sex 339 
hormone levels. Both hormones were given at levels exceeding estrus levels (E2: ±150 pg/ml, P:±25 340 
ng/ml) around a factor of 2 (E2: ±350 pg/ml, P:±55 ng/ml) (50). In sexually mature animals these 341 
levels have been shown to promote lung inflammation and T helper 2 responses when exposed to 342 
allergens, and also to induce regulatory T cells in healthy animals (18, 35, 36, 56, 57). However, in our 343 
case estrogen substitution after ovariectomy strongly inhibited lung inflammation and this was 344 
accompanied with lower numbers of regulatory T cells, while progesterone substitution had no effect 345 
at all as compared to untreated ovariectomy. It therefore seems likely that estrogen substitution 346 
induces changes in immune gene expression or immune function that is still possible in sexually 347 
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immature animals but can no longer occur in animals that have gone through normal sexual 348 
maturation. The fact that normal sexual maturation only moderately protects against lung 349 
inflammation as compared to the strong protection of estrogen substitution, may be explained by 350 
the lack of corresponding progesterone increases in our model. The increasing levels of progesterone 351 
may counteract the effects of estrogen during normal development. The importance of the ratio of 352 
circulating estrogen-to-progesterone levels in the response to allergens was recently also suggested 353 
by others (37, 57).  354 
To elucidate the mechanism behind the estrogen-mediated protective effects on lung inflammation, 355 
we first focused on quantifying known pro-asthmatic mediators like TSLP and IL-33. Our previous 356 
studies in males and females did not show differences in TSLP (32), so we decided to study IL-33 first. 357 
We found its expression to be significantly lower in lung parenchyma of ovariectomized mice treated 358 
with estrogen as compared to untreated ovariectomized mice. IL-33 is a member of the IL-1 family 359 
and it activates group 2 innate lymphoid cells (ILC2 cells), Th2 lymphocytes and mast cells to secrete 360 
Th2 cytokines and chemokines leading to allergic inflammation (24, 49, 51). IL-33 expression in the 361 
lung is higher in asthmatics than healthy controls (5, 42, 45) and polymorphisms in the IL-33 gene 362 
have been associated with the development of asthma (47). In humans IL-33 expression has mainly 363 
been shown in bronchial epithelial cells, but we found that IL-33 in mice was solely expressed in type 364 
II alveolar epithelial cells, confirming that there are species-specific differences between human and 365 
mice in IL-33 expression (41).  366 
Currently, little is known about the molecular mechanisms involved in production of IL-33 (21), but 367 
the NF-B signaling pathway appears to be involved. In human corneal epithelial cells it was 368 
demonstrated that IL-33 was produced in response to microbial pathogens through Toll like receptor 369 
(TLR)/NF-B signaling pathways (61). The same mechanism was confirmed in a newly identified 370 
source of IL-33, i.e. dendritic cells (53). We therefore further investigated mediators known to inhibit 371 
the NF-B signaling pathway to explain how estrogen may inhibit IL-33 expression. 372 
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Previously, Chotirmall et al. found that estrogen inhibits the expression of the NF-B-dependent 373 
chemokine IL-8 in bronchial epithelial cells by upregulating SLPI. There is a partial estrogen response 374 
element in the SLPI promoter and they showed that E2 upregulates expression of SLPI in bronchial 375 
epithelial cells via estrogen receptor-β (9). SLPI is known to inhibit NF-B activation by binding 376 
directly to NF-B binding sites in a site-specific manner (54) and we therefore investigated the 377 
expression of SLPI in our model and indeed found higher levels in lavage fluid and lung parenchyma 378 
of estrogen-treated ovariectomized mice than in lungs of ovariectomized mice. The highest SLPI 379 
expression was found in the lung parenchyma and double stainings revealed that SLPI was also 380 
produced by AECII. Since these are the same cells that expressed IL-33, we performed double 381 
stainings for SLPI and IL-33. Interestingly, these mediators did not colocalize, meaning that the same 382 
cell did not express SLPI and IL-33 at the same time. High expression of SLPI in lung tissue was 383 
associated with low expression of IL-33, and vice versa. This suggested to us a direct inhibitory effect 384 
of SLPI on IL-33 expression, a finding confirmed in our in vitro model of ATP-induced IL-33 production 385 
by AECII. Of relevance to asthma, OVA-sensitized and challenged mice have increased levels of ATP in 386 
the lungs and extracellular ATP modifies the recruitment/function of inflammatory cells, suggesting 387 
that it is a key mediator in asthma (19). In response to extracellular ATP, IL-33 expression was higher 388 
in AECII cells, but the production was significantly lower when SLPI was added. These findings 389 
confirm the anti-inflammatory effects of SLPI as described previously in monocytes (12). Exogenously 390 
applied SLPI to monocytes is taken up into the cells and is distributed in the cytoplasm and nucleus. 391 
There it blocks NF-B activation by inhibiting the degradation of IBa and IBb and by competing 392 
with p65 for binding to NF-κB sites in the promoters of NF-κB-responsive genes and inhibits the 393 
production of pro-inflammatory cytokines (15, 54, 55).  394 
Taken together, our data show that the sexual maturation (puberty) ameliorates the development of 395 
lung inflammation in mice. This protective effect of ‘puberty’ appears to be dependent on estrogen 396 
and may be induced by production of the anti-inflammatory mediator SLPI and thereby inhibition of 397 
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production of pro-inflammatory IL-33 in parenchymal lung tissue. These data provide a new 398 
perspective regarding the role of the female sex hormones estrogen and progesterone in asthma 399 
pathogenesis. 400 
401 
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Figure legends 574 
Figure 1. Experimental design of the study. OVX, ovariectomy; SHAM, SHAM-operated mice; OVA, 575 
ovalbumin; i.p., intra-peritoneal. 576 
Figure 2. Hematoxylin and eosin staining of healthy, SHAM-treated, OVX, OVX+P and OVX+E2 mice. 577 
Sham-treated, OVX and OVX+P mice responded to OVA challenges with lung inflammation and 578 
thickening of the alveolar walls. OVX mice treated with estrogen demonstrated less lung 579 
inflammation and no thickening of the alveolar walls (magnification 100x). 580 
Figure 3. Inflammatory parameters in bronchoalveloar lavage fluid, lung tissue and serum of healthy, 581 
SHAM-treated, OVX, OVX+E2 and OVX+P mice. Higher numbers of eosinophils, (activated) 582 
macrophages and B lymphocytes were induced in lungs of OVA-exposed SHAM-treated mice as 583 
compared to healthy controls. OVX mice had higher numbers of eosinophils in lavage fluid and B 584 
lymphocytes in lung tissue as compared to SHAM-treated mice and significantly lower numbers of 585 
eosinophils, activated/macrophages and B lymphocytes were found in OVX mice treated with 586 
estrogen as compared to untreated OVX mice (A, B, C and D). Higher levels of OVA-specific IgE were 587 
detected in serum of SHAM-treated mice as compared to healthy mice. OVA-specific IgE levels in 588 
serum were not significantly affected by OVX, but OVX mice treated with estrogen had lower levels as 589 
compared to untreated OVX mice (E). Higher numbers of effector and regulatory T cells were found in 590 
lung tissue of SHAM-treated mice as compared to healthy mice. OVX did not affect numbers of 591 
effector and regulatory T lymphocytes in lung tissue, but E2 treatment led to significantly lower 592 
numbers of these cells in lung tissue as compared to untreated OVX (F and G). Progesterone 593 
treatment of OVX mice did not affect any of the indicated inflammatory parameters. P<0.01 594 
statistical trend, *P<0.05 and **P<0.01 and ***P<0.001.  595 
Figure 4 Immunohistochemical double stainings for alveolar epithelial cells (pro-SPC, red) and IL-33 596 
(blue) showed colocalization of IL-33 expression in type II epithelial cells (A). Double stainings for 597 
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alveolar epithelial cells (pro-SPC, blue) and SLPI (red) showed colocalization of SLPI expression in type 598 
II epithelial cells (B) (magnification 200x). 599 
Figure 5. SLPI and IL-33 expression in bronchoalveloar lavage fluid and lungs of healthy, SHAM-600 
treated, OVX and OVX+E2 mice. SLPI expression could not be detected in in BALF of healthy mice (ND, 601 
not detected). Lower levels of SLPI were detected in lavage fluid of OVX mice as compared to sham-602 
treated and estrogen-treated OVX mice (A). Representative Western blot quantification of SLPI levels 603 
in lavage fluid of 2 OVX, 1 SHAM and 1 OVX+E2 mice. Blots were rearranged, but all samples were 604 
derived at the same time and processed in parallel (B). OVX+E2 mice had significantly more cells 605 
expressing SLPI than SHAM mice and untreated OVX mice (C). Higher numbers of IL-33 producing cells 606 
were induced in lungs of SHAM-treated mice than in lungs of healthy mice. Lower numbers of IL-33-607 
producing cells were found in OVX+E2 mice as compared to OVX (D). An example of a double staining 608 
of lung tissue of ovariectomized + estrogen-treated mice for SLPI (red) and IL-33 (blue). The double 609 
staining showed no colocalization of IL-33 and SLPI (magnification 200x) (E). *P<0.05, **P<0.01, 610 
***P<0.001 and ****P<0.0001. 611 
Figure 6. Relative IL-33 concentration in C10 type II alveolar epithelial cells. ATP treatment induced 612 
higher levels of IL-33 within cells as compared to control (**P<0.01). After SLPI treatment, the ATP-613 
induced IL-33 production was lower (**P<0.01). SLPI treatment alone did not affect IL-33 levels in 614 
cells.  615 
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